Hilliard Lyons Reiterates Long Term Buy Rating On VIVO

Hilliard Lyons reiterated its "long term buy" rating on Meridian Bioscience Inc. (NASDAQ: VIVO). It estimates VIVO's 2010 EPS at $0.97 and if the company sustains its growth, Hilliard Lyons thinks that Meridian Bioscience's EPS will reach $1.10 in two or three years. Therefore, Hilliard Lyons has a price target of $27 per share.

Hilliard Lyons sees VIVO as reasonably priced company that has a strong financial position and an attractive dividend yield of about 3%.

VIVO's fourth fiscal quarter revenue increased 16% to $42.5M due to emergence of the swine flue. Meridian Bioscience Inc. (VIVO) dropped 1.53% today and closed at $22.50.